Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

To reduce serum phosphate in patients with ESRD FOSRENOL Oral Powder:
Same active ingredient as FOSRENOL Chewable Tablets

  • FOSRENOL Oral Powder has the same active ingredient—lanthanum carbonate—as FOSRENOL Chewable Tablets, a proven phosphate binder that has been available for more than 10 years1,2

Study demonstrates pharmacodynamic equivalence of the two formulations1,†

  • FOSRENOL Oral Powder was shown to be comparable to the chewable tablets in a study (N = 72) that assessed pharmacodynamic equivalence1-3

Based on urinary phosphate excretion in healthy subjects.

Read about clinical trial results for FOSRENOL Chewable Tablets

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information .

Important Safety Information

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information.

References: 1. FOSRENOL [package insert]. Lexington, MA: Shire US Inc. 2. Center for Drug Evaluation and Research. FOSRENOL approval letter. US Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21468ltr.pdf. Published October 26, 2004. Accessed March 29, 2015. 3. Pierce D, Hossack S, Robinson A, Zhang P, Martin P. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects. Clin Ther. 2012:34;1290-1300.